AMCo Amdipharm Mercury Pharmaceuticals

About us

Concordia International is part of the Concordia International Corp, a diverse international company focused on legacy pharmaceutical medicines and orphan drugs [please see our Corporate website here]. We have a strong international footprint and supply a diversified portfolio of more than 200 well-established off-patent molecules to patients, partners and healthcare authorities in more than 100 countries [see our Medicines here]. We have an extensive Environmental, Social & Governance programme [see here]

Read more

Latest News

  • 15/12/2017: Concordia International Corp. Comments on Recent Trading Activity

    Concordia International Corp., today announced that at the request of the Investment Industry Regulatory Organization of Canada ("IIROC"), the Company is confirming that it is unaware at this time of any material change in its operations that would account for the recent increase in market activity.
  • 01/12/2017: Concordia International Corp. Announces Receipt of Nasdaq Initial Notice of Bid Price Requirement

    Concordia International Corp. today announced that on November 29, 2017, it received an initial notification letter from the Listing Qualifications Department of the NASDAQ Global Select Market ("Nasdaq") notifying the Company that it had 180 days to regain compliance with the minimum bid price requirement set forth in Nasdaq's continued listing rules.

More news

More news

Products

"Concordia International is part of the Concordia International Corp, a diverse international company focused on legacy pharmaceutical products and orphan drugs. We have a number of product ranges, including Concordia products, Amdipharm products, Mercury Pharma products, Abcur products, BnM products and Focus Pharma products. For more information please visit our Products page."

Our Products